Scientists
at the University of Bristol, together with collaborators at the University of
Aveiro, Portugal, have solved the structure of an enzyme that breaks down carbapenems
, antibiotics 'of last resort' which, until recently, were kept in reserve for
serious infections that failed to respond to other treatments.
Carbapenemases
are members of the group of enzymes called beta-lactamases that break down
penicillins and related antibiotics.
Using
molecular dynamics simulations, Professor Adrian Mulholland in the School of
Chemistry and Dr Jim Spencer in the School of Cellular and Molecular Medicine,
showed how a particular type of carbapenemase enzyme reorients bound antibiotic
to promote its breakdown and render it ineffective.
In
a study published in the Journal of the American Chemical Society (JACS), the
scientists combined laboratory experiments with computer simulations to
investigate how one particular type of carbapenemase recognises and breaks down
antibiotics.
Using
X-ray crystallography, they obtained two 'snapshots' of the carbapenemase in
the act of breaking down a carbapenem antibiotic. This static structural
information was used as a starting point for simulations that modelled the
motions of the enzyme and the bound antibiotic.
The
simulations showed how the carbapenemase reorients the drug to promote its
breakdown. In beta-lactamases that cannot break down carbapenems, this
rearrangement cannot happen, and so the enzyme cannot break down the
antibiotic. Knowing this should help in designing new drugs that can resist
being broken down.
For
further details, see:
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources